JANX
Janux Therapeutics, Inc.
Key Financials
Operating Income
$-157667000
↓ 59.5%
Net Income
$-113625000
↓ 64.7%
Total Assets
$1.0B
↓ 5.6%
EPS (Diluted)
$-1.83
↓ 43.0%
Shareholders' Equity
$956.8M
↓ 6.4%
Total Liabilities
$44.7M
↑ 15.5%
Cash & Equivalents
$52.3M
↓ 87.8%
Operating Cash Flow
$-82235000.00
↓ 87.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 4 | 5/13/2026 | View on SEC |
| SCHEDULE 13G | 5/12/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| SCHEDULE 13G/A | 5/6/2026 | View on SEC |
| SCHEDULE 13G | 4/29/2026 | View on SEC |
| SCHEDULE 13G | 4/29/2026 | View on SEC |
| 8-K | 4/28/2026 | View on SEC |
| ARS | 4/28/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | JANX |
| Company Name | Janux Therapeutics, Inc. |
| CIK | 1817713 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 751-4493 |